US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Altimmune, Inc. - Common Stock (NQ:ALT)

2.670 -0.060 (-2.20%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
ALTIMMUNE INC (ALT) Q1 2021 Earnings Call Transcript ↗
ALT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For May 17, 2021 ↗
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
News headline image
Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗
On Tuesday, Altimmune stock received a positive adjustment to its Relative Strength Rating, from 78 to 86. The biopharma stock is worth watching. 
Via Investor's Business Daily
News headline image
Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose ↗
Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-... 
Via Benzinga
News headline image
Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects? ↗
The short answer: It depends. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >